Integrity,Innovation,Reliability,Responsibility

Latest Progress on the Clinical Trial of Multiple-Dose Drug-Drug Interaction Between HP515 Tablets and Semaglutide Injection in Overweight/Obese Participants

Time:2026-03-31 Source:海创药业 Hits:108

Hinova Pharmaceuticals Co., Ltd. (hereinafter referred to as "the Company") has recently completed the enrollment of the first participant in the clinical trial evaluating the multiple-dose drug-drug interaction between HP515 tablets, a THR-β agonist independently developed by the Company, and semaglutide injection in overweight/obese participants.


About HP515


HP515 tablets are an oral, highly selective THR-β (thyroid hormone receptor beta) agonist independently developed by the Company. HP515 directly acts on THR-β to activate downstream gene transcription, improving metabolic dysfunction-associated steatohepatitis by enhancing hepatocellular lipid metabolism, promoting hepatic fat metabolism, and reducing lipotoxicity. The Company is currently developing HP515 for the treatment of metabolic dysfunction-associated fatty liver disease / metabolic dysfunction-associated steatohepatitis (MAFLD/MASH) and obesity. HP515 received approval from China's National Medical Products Administration (NMPA) in August 2024 for the treatment of metabolic steatohepatitis (MASH), and received approval from the U.S. Food and Drug Administration (FDA) in September 2024 for the treatment of MASH.


The Company has completed the Phase I clinical trial of HP515. Preliminary data indicate that HP515 met expectations in terms of safety, tolerability, pharmacokinetics, and pharmacodynamics. Under conditions of 40 mg, 60 mg, and 80 mg once-daily dosing for 14 consecutive days, SHBG (sex hormone-binding globulin) showed a significant dose-dependent increase from baseline. At the 80 mg dose, SHBG increased by 176% after 14 days of dosing, indicating that HP515 exerts its pharmacological effects through activation of the endogenous THR-β receptor. Meanwhile, several lipid parameters showed significant improvement following HP515 treatment: LDL-C (low-density lipoprotein cholesterol), TC (total cholesterol), and ApoB (apolipoprotein B) demonstrated significant dose-dependent reductions from baseline. At the 80 mg dose, LDL-C decreased by 39%, TC decreased by 28%, and ApoB decreased by 41%.


The Phase IIa clinical trial of HP515 has recently completed enrollment of all participants. This study is a clinical trial evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of HP515 in participants with metabolic dysfunction-associated fatty liver disease. As of the date of this release, no products targeting the same indication have been approved for marketing in China.


Previously, preclinical research data on HP515 in combination with GLP-1R agonists for the treatment of obesity were presented as an oral report at the 32nd European Congress on Obesity (ECO) 2025 and were selected for poster presentation at The 3rd Obesity & Weight Loss Drug Development Summit in June 2025, signifying international recognition of the related research data by top-tier academic conferences.


An abstract of the Phase I clinical trial of HP515 for the treatment of MASH will be presented as a poster at the EASL Congress 2026 (European Association for the Study of the Liver Congress 2026) on May 29, 2026.


Disclaimer:

1. This article is intended solely to share updates on academic frontiers and is for reference by healthcare professionals for academic purposes only. It is not promotional material. Hinova Pharmaceuticals does not make any recommendation, commitment, or guarantee regarding any drug or indication.

2. The information contained herein is derived from relevant research reports and clinical data and is for reference only. Please follow the guidance of physicians or other qualified healthcare professionals.

3. Any information involving unapproved products refers to assets still in development or clinical trials and involves uncertainties. Final outcomes are subject to approval by the National Medical Products Administration.